Morgan Stanley Knock-Out GILD/ DE000ME3P8W8 /
| 08/11/2024 21:27:55 | Var.-0.04 | Denaro22:00:01 | Lettera22:00:01 | Sottostante | Prezzo di esercizio | Expiration date | Tipo di opzione |
|---|---|---|---|---|---|---|---|
| 4.91EUR | -0.81% | - Quantità in denaro: - |
- Quantità in lettera: - |
Gilead Sciences Inc | 44.0236 USD | 31/12/2078 | Call |
GlobeNewswire
08/08
HOOKIPA Pharma Reports Second Quarter 2024 Financial Results and Recent Business Highlights
GlobeNewswire
08/08
Assembly Biosciences Reports Second Quarter 2024 Financial Results and Recent Updates
GlobeNewswire
08/08
Xilio Therapeutics Announces Pipeline and Business Updates and Second Quarter 2024 Financial Results
GlobeNewswire
06/08
MacroGenics Provides Update on Corporate Progress, Second Quarter 2024 Financial Results
GlobeNewswire
01/08
Merus Announces Financial Results for the Second Quarter 2024 and Provides Business Update
GlobeNewswire
23/07
ACTG Presents Data Analysis at AIDS 2024 Showing Association between Elevated Risk of Cardiovascular...
GlobeNewswire
15/07
Assembly Biosciences Presents New Preclinical Data Highlighting Investigational Helicase-Primase Inh...
GlobeNewswire
01/07
HOOKIPA Pharma Announces First Person Dosed in Phase 1b Clinical Trial of HB-500 for the Treatment o...
GlobeNewswire
01/07
Vera Therapeutics Announces Appointment of Industry Veteran David L. Johnson as Chief Operating Offi...
GlobeNewswire
28/06
Ensho Therapeutics Launches with Phase 2-Ready Oral α4β7 Inhibitor for Inflammatory Bowel Disease
GlobeNewswire
26/06
Neurona Therapeutics Appoints Dr. Nadia Agopyan as Senior Vice President of Regulatory Affairs
GlobeNewswire
26/06
Oruka Therapeutics Announces Key Additions to Leadership Team and Board of Directors
GlobeNewswire
18/06
Assembly Biosciences Doses First Participant in Phase 1b Clinical Trial Evaluating Next-Generation C...
GlobeNewswire
10/06
Assembly Biosciences Doses First Participant in Phase 1a/b Clinical Trial of Herpes Simplex Virus He...
